![]() |
|||||||
|
Fusion Protein:CHSY3-FBXL17 |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: CHSY3-FBXL17 | FusionPDB ID: 16736 | FusionGDB2.0 ID: 16736 | Hgene | Tgene | Gene symbol | CHSY3 | FBXL17 | Gene ID | 337876 | 64839 |
Gene name | chondroitin sulfate synthase 3 | F-box and leucine rich repeat protein 17 | |
Synonyms | CHSY2|CSS3 | FBXO13|Fbl17|Fbx13 | |
Cytomap | 5q23.3 | 5q21.3 | |
Type of gene | protein-coding | protein-coding | |
Description | chondroitin sulfate synthase 3N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase 3N-acetylgalactosaminyltransferase 3carbohydrate synthase 2chSy-2chondroitin glucuronyltransferase 3chondroitin synthase-2glucuronosyl-N-acetylgalactos | F-box/LRR-repeat protein 17F-box only protein 13 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q70JA7 Main function of 5'-partner protein: FUNCTION: Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Specific activity is much reduced compared to CHSY1. {ECO:0000269|PubMed:12907687}. | Q9UF56 Main function of 5'-partner protein: FUNCTION: Substrate-recognition component of the SCF(FBXL17) E3 ubiquitin ligase complex, a key component of a quality control pathway required to ensure functional dimerization of BTB domain-containing proteins (dimerization quality control, DQC) (PubMed:30190310). FBXL17 specifically recognizes and binds a conserved degron of non-consecutive residues present at the interface of BTB dimers of aberrant composition: aberrant BTB dimer are then ubiquitinated by the SCF(FBXL17) complex and degraded by the proteaseome (PubMed:30190310). The ability of the SCF(FBXL17) complex to eliminate compromised BTB dimers is required for the differentiation and survival of neural crest and neuronal cells (By similarity). The SCF(FBXL17) complex mediates ubiquitination and degradation of BACH1 (PubMed:24035498, PubMed:30190310). The SCF(FBXL17) complex is also involved in the regulation of the hedgehog/smoothened (Hh) signaling pathway by mediating the ubiquitination and degradation of SUFU, allowing the release of GLI1 from SUFU for proper Hh signal transduction (PubMed:27234298). The SCF(FBXL17) complex mediates ubiquitination and degradation of PRMT1 (By similarity). {ECO:0000250|UniProtKB:B1H1X1, ECO:0000250|UniProtKB:Q9QZN1, ECO:0000269|PubMed:24035498, ECO:0000269|PubMed:27234298, ECO:0000269|PubMed:30190310}. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000507545, ENST00000305031, | ENST00000359660, ENST00000496714, ENST00000542267, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 9 X 6 X 5=270 | 14 X 13 X 5=910 |
# samples | 10 | 13 | |
** MAII score | log2(10/270*10)=-1.43295940727611 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(13/910*10)=-2.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: CHSY3 [Title/Abstract] AND FBXL17 [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: CHSY3 [Title/Abstract] AND FBXL17 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CHSY3(129244053)-FBXL17(107684231), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | CHSY3-FBXL17 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CHSY3-FBXL17 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CHSY3-FBXL17 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CHSY3-FBXL17 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | FBXL17 | GO:0000209 | protein polyubiquitination | 27234298 |
Tgene | FBXL17 | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 30190310 |
Tgene | FBXL17 | GO:0016567 | protein ubiquitination | 24035498|30190310 |
Tgene | FBXL17 | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 24035498|27234298 |
Tgene | FBXL17 | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 30190310 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:129244053/chr5:107684231) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000305031 | CHSY3 | chr5 | 129244053 | + | ENST00000359660 | FBXL17 | chr5 | 107684231 | - | 4861 | 1444 | 358 | 2175 | 605 |
ENST00000305031 | CHSY3 | chr5 | 129244053 | + | ENST00000542267 | FBXL17 | chr5 | 107684231 | - | 4851 | 1444 | 358 | 2175 | 605 |
ENST00000305031 | CHSY3 | chr5 | 129244053 | + | ENST00000496714 | FBXL17 | chr5 | 107684231 | - | 4835 | 1444 | 358 | 2208 | 616 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000305031 | ENST00000359660 | CHSY3 | chr5 | 129244053 | + | FBXL17 | chr5 | 107684231 | - | 0.000321485 | 0.9996785 |
ENST00000305031 | ENST00000542267 | CHSY3 | chr5 | 129244053 | + | FBXL17 | chr5 | 107684231 | - | 0.000316932 | 0.99968314 |
ENST00000305031 | ENST00000496714 | CHSY3 | chr5 | 129244053 | + | FBXL17 | chr5 | 107684231 | - | 0.001384081 | 0.99861586 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for CHSY3-FBXL17 |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
CHSY3 | chr5 | 129244053 | FBXL17 | chr5 | 107684231 | 1444 | 362 | RRFGGTQCVWSYELGSKCRELKDIHF |
Top |
Potential FusionNeoAntigen Information of CHSY3-FBXL17 in HLA I |
![]() |
CHSY3-FBXL17_129244053_107684231.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B08:01 | ELGSKCREL | 0.9741 | 0.8251 | 12 | 21 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B48:01 | TQCVWSYEL | 0.926 | 0.9214 | 5 | 14 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B13:02 | TQCVWSYEL | 0.7656 | 0.8145 | 5 | 14 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B13:01 | TQCVWSYEL | 0.6566 | 0.9873 | 5 | 14 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B08:18 | ELGSKCREL | 0.9741 | 0.8251 | 12 | 21 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B39:02 | TQCVWSYEL | 0.92 | 0.9635 | 5 | 14 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B40:21 | TQCVWSYEL | 0.6537 | 0.87 | 5 | 14 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B08:12 | ELGSKCREL | 0.6513 | 0.8546 | 12 | 21 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B40:04 | YELGSKCREL | 0.9875 | 0.5914 | 11 | 21 |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 | HLA-B41:03 | YELGSKCREL | 0.8286 | 0.5856 | 11 | 21 |
Top |
Potential FusionNeoAntigen Information of CHSY3-FBXL17 in HLA II |
![]() |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of CHSY3-FBXL17 |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
7172 | QCVWSYELGSKCRE | CHSY3 | FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 1444 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CHSY3-FBXL17 |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 7172 | QCVWSYELGSKCRE | -7.68771 | -7.81071 |
HLA-B14:02 | 3BVN | 7172 | QCVWSYELGSKCRE | -4.08432 | -6.53332 |
HLA-B14:02 | 3BVN | 7172 | QCVWSYELGSKCRE | -3.88513 | -4.93003 |
HLA-B52:01 | 3W39 | 7172 | QCVWSYELGSKCRE | -6.7782 | -6.9012 |
HLA-B52:01 | 3W39 | 7172 | QCVWSYELGSKCRE | -5.97951 | -8.42851 |
HLA-B52:01 | 3W39 | 7172 | QCVWSYELGSKCRE | -5.46508 | -6.50998 |
HLA-B52:01 | 3W39 | 7172 | QCVWSYELGSKCRE | -5.30357 | -5.42657 |
HLA-B52:01 | 3W39 | 7172 | QCVWSYELGSKCRE | -5.21706 | -7.66606 |
HLA-B52:01 | 3W39 | 7172 | QCVWSYELGSKCRE | -4.67432 | -5.71922 |
HLA-A11:01 | 4UQ2 | 7172 | QCVWSYELGSKCRE | -4.07287 | -5.11777 |
HLA-A24:02 | 5HGA | 7172 | QCVWSYELGSKCRE | -6.77765 | -6.90065 |
HLA-A24:02 | 5HGA | 7172 | QCVWSYELGSKCRE | -5.63472 | -8.08372 |
HLA-A24:02 | 5HGA | 7172 | QCVWSYELGSKCRE | -4.34838 | -5.39328 |
HLA-B27:05 | 6PYJ | 7172 | QCVWSYELGSKCRE | -1.14017 | -3.58917 |
HLA-B44:05 | 3DX8 | 7172 | QCVWSYELGSKCRE | -6.67859 | -6.80159 |
HLA-B44:05 | 3DX8 | 7172 | QCVWSYELGSKCRE | -5.89835 | -6.94325 |
HLA-B44:05 | 3DX8 | 7172 | QCVWSYELGSKCRE | -5.73734 | -5.86034 |
HLA-B44:05 | 3DX8 | 7172 | QCVWSYELGSKCRE | -5.28434 | -7.73334 |
HLA-B44:05 | 3DX8 | 7172 | QCVWSYELGSKCRE | -4.71989 | -5.76479 |
HLA-B44:05 | 3DX8 | 7172 | QCVWSYELGSKCRE | -4.36755 | -6.81655 |
Top |
Vaccine Design for the FusionNeoAntigens of CHSY3-FBXL17 |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 11 | 21 | YELGSKCREL | TACGAGCTGGGCTCAAAATGCAGAGAACTC |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 12 | 21 | ELGSKCREL | GAGCTGGGCTCAAAATGCAGAGAACTC |
CHSY3-FBXL17 | chr5 | 129244053 | chr5 | 107684231 | 5 | 14 | TQCVWSYEL | ACTCAGTGTGTCTGGTCTTACGAGCTG |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of CHSY3-FBXL17 |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
STAD | CHSY3-FBXL17 | chr5 | 129244053 | ENST00000305031 | chr5 | 107684231 | ENST00000359660 | TCGA-D7-6822-01A |
Top |
Potential target of CAR-T therapy development for CHSY3-FBXL17 |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | CHSY3 | chr5:129244053 | chr5:107684231 | ENST00000305031 | + | 2 | 3 | 8_28 | 362 | 883.0 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to CHSY3-FBXL17 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to CHSY3-FBXL17 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |